OIO. Ihnatko

O. Ihnatko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. Ihnatko has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS C COMBINED WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY AFTER COMPREHENSIVE THERAPY

    by M Derbak, N Lizanets, O Ihnatko, Ya. Ihnatko, L Ihnatko

    The aim of this study was to assess the effectiveness of combined therapy using ademetionine and ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and obesity. The main objective was to evaluate how this treatment regimen affects clinical indicators, liver function, and overall quality of life, particularly physical and psychological well-being.Materials and methods. A prospective study involved 70 patients with verified CHC diagnosis, NAFLD and obesity. The average age of patients was 58.5 ± 1.5 years. A control group (n = 25, average age 33.2 ± 1.5 years) consisted of healthy individuals.The participants were divided into three groups. The first group received standard antiviral therapy. The second group received antiviral therapy plus ademetionine, and the third group received a combination of ademetionine and UDCA along with antiviral therapy. Quality of life was assessed using SF-36 and EQ-5D questionnaires at the beginning of treatment, and after three and six months of therapy.Results. Patients receiving the combined treatment with ademetionine and UDCA showed the most significant improvements in quality of life, particularly in physical function, pain reduction, and mental health. They reported decreased anxiety and depression and improved social activity. Those receiving antiviral therapy with ademetionine also showed improvement, but to a lesser degree.No significant changes were observed in the control group.Conclusion. Combined therapy with ademetionine and UDCA alongside antiviral treatment is an effective approach for patients with CHC, NAFLD, and obesity, improving both clinical outcomes and quality of life, particularly in physical and psychological domains. Мета наукового дослідження полягала в оцінці ефективності комплексної терапії, що включала адеметіонін та урсодезоксихолеву кислоту (УДХК), для поліпшення якості життя у пацієнтів з хронічним гепатитом С (ХГС), поєднаним із неалкогольною жировою хворобою печінки (НАЖХП) та ожирінням. Основним завданням було оцінити, як таке лікування впливає на клінічні показники здоров’я, а також на загальну якість життя пацієнтів, зокрема фізичну та психічну активність.Матеріали та методи. У дослідженні взяли участь 70 пацієнтів, які хворіли на ХГС з супутньою НАЖХП та ожирінням.Всі пацієнти мали підтверджений діагноз ХГС, який був верифікований на основі серологічних та молекулярно-генетичних методів, а також результатів ультразвукових досліджень печінки, що свідчили про наявність НАЖХП. Середній вік пацієнтів становив 58,5±1,5 років. Для порівняння, контрольну групу склали 25 здорових осіб, які не мали хронічні захворювання печінки та метаболічні розлади.Пацієнти були розподілені на три групи. Перша група отримувала стандартну терапію прямими противірусними препаратами (ПППД). Друга група крім ПППД отримувала адеметіонін, а третя – комплексну терапію з додаванням як адеметіоніну, так і УДХК. Для оцінки якості життя пацієнтів використовували два стандартизовані опитувальники: SF-36 (для оцінки фізичного та психічного компонентів здоров'я) і EQ-5D (для загальної оцінки функціонального стану та життєвої активності).Обстеження проводилось на початку лікування, через три місяці та через шість місяців після початку терапії.Результати. Усі групи продемонстрували певне покращення показників якості життя, однак найбільш виражене покращення спостерігалося в групі, що отримувала комплексну терапію з адеметіоніном та УДХК. У порівнянні з початковими даними, пацієнти цієї групи продемонстрували статистично значуще зменшення інтенсивності болю, поліпшення фізичної функціональності, зниження рівня тривожності та депресії. Також у них спостерігалося значне поліпшення показників соціального функціонування та здатності до виконання щоденних справ. Пацієнти, які отримували тільки ПППД та адеметіонін, також продемонстрували покращення якості життя, але результати були менш вираженими порівняно з тими, хто проходив комплексну терапію. Пацієнти контрольної групи не мали значущих змін у...

  • Open Access

    Quality of Life Indices in Patients with Coronary Heart Disease with Stable Angina Pectoris Accompanied by Non-alcoholic Steatohepatitis after Complex Treatment Supplemented with Ezetimibe and Ursodeoxycholic Acid

    by I. Chopey, Ya. Ihnatko, M. Derbak, K. Chubirko, O. Ihnatko, V. Hadzheha

    Introduction. Coronary heart disease (CHD) is often complicated by the presence of concomitant diseases, especially non-alcoholic fatty liver disease (NAFLD). According to the data from numerous studies, it is known that the number of cardiovascular complications in patients with NAFLD is increasing. This negatively affects the clinical course of both diseases, worsens the quality of life of patients and increases the percentage of cardiovascular mortality among the population. The aim of the study. To evaluate the quality of life indicators in patients with coronary heart disease with stable angina pectoris in combination with nonalcoholic steatohepatitis after complex therapy including ezetimibe and ursodeoxycholic acid. Materials and methods. The study involved 145 patients with a verified diagnosis of coronary heart disease, stable angina pectoris II functional class combined with nonalcoholic steatohepatitis (NASH) and 100 patients with coronary heart disease without NASH. There were 140 men (57.0 %), and 105 women (43.0 %). The average age of patients is 55.3 ± 6.3 years. Results. A decrease in the number of angina attacks and the need to use nitroglycerin per week was registered in patients with coronary artery disease in combination with NASH under the influence of the treatment, which was more pronounced in the group with the addition of ezetimibe and ursodeoxycholic acid (UDCA). According to the Medical Outcomes Study 36-Item Short-Form Health Status (SF-36) questionnaire after treatment, a tendency to improve most of its indicators was revealed, which was more clearly observed in patients in the group with the addition of ezetimibe and UDCA. Also, according to the EuroQoL-5D (EQ-5D) questionnaire, significant positive dynamics of the quality of life were found for all indicators, which were more reliably increased in the group with the addition of ezetimibe and UDCA. According to the Seattle Angina Questionnaire (SAQ), after treatment, reliable positive changes on 4 scales were observed in patients in the group with the addition of ezetimibe and UDCA. Conclusion. The inclusion of ezetimibe and ursodeoxycholic acid in the basic therapy has a positive effect on the clinical course of coronary heart disease in combination with non-alcoholic steatohepatitis, the quality of life of patients and the patient's attitude to his disease.

  • Open Access

    THE ROLE OF PEPSINOGENS IN THE FORMATION OF GERD IN PATIENTS WITH COPD

    by Olesіa Lіakh, Marianna Tovt-Korshуnska

    The article presents data on the role of pepsinogen-1 and -2 and bilirubin in the formation of gastroesophageal reflux disease (GERD) in patients with chronic obstructive pulmonary disease (COPD). Clinical, biochemical, immunological research methods were used in the work. The activity of pepsinogens 1 and 2 and bilirubin in saliva was determined in all patients with combined pathology. It has been established that the presence of concomitant GERD in patients is an independent aggravating factor for the function of external respiration. In patients with concomitant GERD, a significant increase in acute phase parameters in the serum, indicating active systemic inflammation. Increased activity of the cytokine IL-6 and IFNγ indicates the activation of the cellular immune system, with an unregulated immune response that supports chronic inflammation in the bronchi even in remission. Increased levels of IL-4 are compensatory in nature, as IL-4 inhibits the production of macrophages of proinflammatory cytokines, including IL-6. Detection of correlations between the concentration of total bilirubin in saliva with a decrease in external respiration, namely FVC, FEV-1, as well as the presence of shortness of breath allows us to consider bilirubin as a possible marker of reflux and respiratory inflammation in the bronchi, until obstruction. The positive correlation of pepsinogen-1 in saliva with an allergic history, and pepsinogen-2 in saliva with cough, shortness of breath and smoking, and a negative correlation of pepsinogen-1 with the value of FEV1 / FVC, allows to consider pepsinogen-1 and pepsinogen-2 as markers of non-acid reflux and respiratory inflammation with bronchoobstruction

  • Open Access

    Clinical Characteristics of the Combined Course of Chronic Obstructive Pulmonary Disease and Gastroesophagal Reflux Disease

    by O. I. Lіakh, M. I. Tovt-Korshуnska, M. A. Derbak

    The comorbid diseases can occur at any stage of bronchial obstruction, and, regardless of the severity or phase of chronic obstructive pulmonary disease, significantly affect disability, increase the frequency of hospitalizations, and increase the cost of medical care. The presence of concomitant gastroesophageal reflux disease in patients with chronic obstructive pulmonary disease is an independent aggravating risk factor for exacerbations and is associated with health deterioration of this group of patients. The purpose of the study was to study the features of the clinical course of chronic obstructive pulmonary disease in combination with gastroesophageal reflux disease. Materials and methods. Retrospective analysis of 138 patients who were treated in the pulmonology department for exacerbation of the disease and outpatient treatment by a gastroenterologist was carried out. 3 groups of patients were formed: 1 group (n=60) – patients with chronic obstructive pulmonary disease in combination with gastroesophageal reflux disease, 2 group (n=42) – patients with chronic obstructive pulmonary disease without signs of gastroesophageal reflux disease, who were treated in the pulmonology department for exacerbation of the disease and 3 group (n=36) – patients with gastroesophageal reflux disease who were treated on an outpatient basis. The patients were similar in age, stage of disease and duration of illness. The average age of the patients was 55±1.64. It should be noted, regarding the gender characteristics of the groups, that among the examined patients by gender, men predominated – 78.4% (80 out of 102). Results and discussion. The main clinical and anamnestic features of the combined pathology were studied. The significance of the assessment of functional changes in spirometry indexes in this category of patients is described. A significant decrease in external respiration function was revealed in the indicators of the external respiration function in patients of all groups. In the patients with chronic obstructive pulmonary disease in combination with gastroesophageal reflux disease the frequency of exacerbations increases. These exacerbations were associated with the presence and severity of gastrointestinal symptoms, namely increased heartburn, acid regurgitation causes worsening of respiratory symptoms, until the exacerbation of the disease with subsequent hospitalization. Also the length of stay in the hospital of the patients in this group increased by 1.5±0.4 days, which is associated with a severe exacerbation of chronic obstructive pulmonary disease and the need to use a double dose of glucocorticoids to control the symptoms of respiratory failure. Among the complaints of patients with combined pathology, extraesophageal manifestations of gastroesophageal reflux disease prevailed. Conclusion. The presence of concomitant gastroesophageal reflux disease in patients with chronic obstructive pulmonary disease expands and aggravates the clinical manifestations of the underlying disease